AB Science S.A. (EPA:AB)
France · Delayed Price · Currency is EUR 1.182
-0.036 (-2.96%)
Apr 2, 2026, 5:35 PM CET
AB Science Revenue
AB Science had revenue of 515.00K EUR in the half year ending June 30, 2025, with 14.96% growth. This brings the company's revenue in the last twelve months to 1.03M, down -5.08% year-over-year. In the year 2024, AB Science had annual revenue of 1.07M with 10.52% growth.
Revenue (ttm)
1.03M
Revenue Growth
-5.08%
P/S Ratio
83.96
Revenue / Employee
28.53K
Employees
36
Market Cap
86.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.07M | 102.00K | 10.52% |
| Dec 31, 2023 | 970.00K | 12.00K | 1.25% |
| Dec 31, 2022 | 958.00K | -649.00K | -40.39% |
| Dec 31, 2021 | 1.61M | 24.00K | 1.52% |
| Dec 31, 2020 | 1.58M | 12.00K | 0.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 46.72B |
| EssilorLuxottica Société anonyme | 28.49B |
| Ipsen | 3.93B |
| Sartorius Stedim Biotech | 2.97B |
| Guerbet | 798.67M |
| Eurofins-Cerep | 38.86M |
| Adocia | 12.88M |
| Innate Pharma | 9.01M |
AB Science News
- 5 weeks ago - AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS - GlobeNewsWire
- 7 weeks ago - Stonegate Capital Partners Initiates Coverage on AB Science S.A. (AB) - Newsfile Corp
- 7 weeks ago - AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors - GlobeNewsWire
- 2 months ago - AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041 - GlobeNewsWire
- 3 months ago - AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia - GlobeNewsWire
- 3 months ago - AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040 - GlobeNewsWire
- 3 months ago - AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share - GlobeNewsWire
- 3 months ago - AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers - GlobeNewsWire